Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1761 to 1770 of 2603 total matches.

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
the last Medical Letter article on this subject, consensus guidelines have been published.1 ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
, and pain. Early use of disease-modifying therapy has improved clinical outcomes.1,2 PARENTERAL DRUGS ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

In Brief: FDA Warning on Dronedarone (Multaq)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2011  (Issue 1359)
) approved in 2009 for treatment of atrial fibrillation,1,2 has been associated with “several” cases ...
The FDA and the manufacturer (Sanofi-Aventis) have warned healthcare professionals that use of dronedarone (Multaq), an analog of amiodarone (Cordarone, and others) approved in 2009 for treatment of atrial fibrillation,1,2 has been associated with "several" cases of severe liver injury and hepatic failure, including two that required liver transplants. Both transplants were in women about 70 years old; one had taken the drug for 4.5 months and the other for 6 months. According to the FDA, 147,000 patients have taken dronedarone.3 A new warning in the package insert recommends monitoring...
Med Lett Drugs Ther. 2011 Mar 7;53(1359):17 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
in 2020 and 2021.1,2 STANDARD TREATMENT — Patients with acute VTE have traditionally been treated ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
. An increase in serum aminotransferase levels to >3 times the upper limit of normal (ULN) occurs in 1-2 ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Propofol

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990  (Issue 813)
) and midazolam (Versed). PHARMACOLOGY — Propofol is 2,6-diisopropylphenol formulated as a 1% emulsion ...
Propofol (Diprivan - Stuart), a new intravenous (IV) sedative-hypnotic, was recently marketed in the USA for induction of anesthesia, or for maintenance of general anesthesia as part of a balanced anesthesia regimen. Older drugs used in a similar way include thiopental (Pentothal; and others) and midazolam (Versed).
Med Lett Drugs Ther. 1990 Mar 9;32(813):22 |  Show IntroductionHide Introduction

Isosorbide Mononitrate for Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992  (Issue 873)
of $1.32 for generic isosorbide dinitrate (30 mg tid), according to Average Wholesale Price listings ...
Isosorbide mononitrate (ISMN; Ismo - Wyeth-Ayerst), an oral nitrate long available in Europe, was recently approved by the US Food and Drug Administration for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide dinitrate (ISDN; Isordil, and others).
Med Lett Drugs Ther. 1992 Jun 26;34(873):61 |  Show IntroductionHide Introduction

New Treatments for Keratoconus

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011  (Issue 1365)
requiring corneal transplantation. It has an incidence of 1 in 2000 and usually appears in puberty ...
Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation are effective treatments, but intracorneal ring segments and collagen cross-linking procedures offer some new alternatives in the management of the disease.
Med Lett Drugs Ther. 2011 May 30;53(1365):43-4 |  Show IntroductionHide Introduction

Metformin for Prediabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 2016  (Issue 1507)
.1 Metformin has not been approved for such use by the FDA. CLINICAL STUDIES — In the Diabetes ...
The oral biguanide metformin (Glucophage, and others) is generally the drug of choice for initial treatment of type 2 diabetes. It has also been used to prevent or at least delay the onset of diabetes in patients considered to be at high risk for the disease. Recent guidelines recommend considering use of metformin in patients with prediabetes (fasting plasma glucose 100-125 mg/dL, 2-hr post-load glucose 140-199 mg/dL, or A1C 5.7-6.4%), especially in those who are <60 years old, have a BMI >35 kg/m2, or have a history of gestational diabetes. Metformin has not been approved...
Med Lett Drugs Ther. 2016 Nov 7;58(1507):141 |  Show IntroductionHide Introduction

In Brief: Risk of Pulmonary Thromboembolism and Death with Tofacitinib (Xeljanz)

   
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019  (Issue 1579)
thromboembolism and death with a dosage of 10 mg twice daily.1 Tofacitinib is approved for treatment ...
The FDA has required updates to the labeling of the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Xeljanz XR) based on interim results of a postmarketing safety trial that showed an increased risk of pulmonary thromboembolism and death with a dosage of 10 mg twice daily.1 Tofacitinib is approved for treatment of rheumatoid arthritis (RA),2 psoriatic arthritis, and ulcerative colitis.In the postmarketing trial, RA patients ≥50 years old taking methotrexate who had at least one cardiovascular risk factor were randomized to receive add-on treatment with tofacitinib 5 mg twice daily (the...
Med Lett Drugs Ther. 2019 Aug 26;61(1579):136 |  Show IntroductionHide Introduction